Kymera Therapeutics (KYMR) has just started dosing patients in its BREADTH Phase 2b trial for KT-621 in moderate to severe eosinophilic asthma, a clinical milestone that is helping shape current sentiment around the stock.

Alongside this new KT-621 asthma trial and the ongoing BROADEN2 study in atopic dermatitis, Kymera Therapeutics’ recent conference appearances and analyst commentary have kept it in focus. The share price is US$75.94, with a 90 day share price return of 29.46% contributing to a 1 year total shareholder return of 94.52% and a 3 year total shareholder return of 127.50%. This suggests momentum has been strong over both shorter and longer periods despite a 1 day share price return of negative 2.27%.

If this kind of clinical and biotech news has your attention, it could be a good moment to broaden your watchlist with 25 healthcare AI stocks picked out by the Simply Wall St screener.

With Kymera still loss making and trading at US$75.94 after a strong multi year run, the key question now is simple: are investors paying a fair price for KT-621’s potential, or is the market already pricing in future growth?

Most Popular Narrative: 34.9% Undervalued

Kymera Therapeutics’ most followed narrative puts fair value at about $116.71 per share versus the last close of $75.94, framing a sizable valuation gap tied directly to its immunology pipeline and long term earnings potential.

The anticipated Phase II and III trials for their immunology pipeline aim to deliver biologics-like efficacy in oral form. This could enhance net margins by reducing manufacturing costs associated with biologics and by potentially capturing a larger market share.

Curious how this fair value hangs together? The narrative leans heavily on rapid revenue expansion, shifting margins and a future earnings multiple that is unusually elevated for biotechs. Want to see exactly which assumptions carry the most weight?

Result: Fair Value of $116.71 (UNDERVALUED)

However, the narrative can still break if high R&D spend, partner dependence or tougher STAT6 competition undermine the long term earnings power currently reflected in forecasts.

Another View: Price Tag Tells a Different Story

The fair value narrative points to Kymera Therapeutics at about US$116.71 per share, while the current US$75.94 price also sits against a rich P/B of 6.4x versus 2.6x for the broader US biotech group, even though peers average an even higher 11.9x. That mix of premium versus industry but discount versus peers raises a simple question for you: is this a margin of safety or a pricing trap?

Build Your Own Kymera Therapeutics Narrative

If you read this and feel your view is different, or you prefer to work from your own numbers and assumptions instead, you can build a tailored thesis in just a few minutes using Do it your way.

A great starting point for your Kymera Therapeutics research is our analysis highlighting 2 key rewards and 4 important warning signs that could impact your investment decision.

Looking for more investment ideas?

If Kymera has sharpened your curiosity, do not stop here. Use the Simply Wall St screener to spot other opportunities that might fit your style.

• Target potential mispricings by reviewing companies our screener flags as 55 high quality undervalued stocks. These might warrant a closer look on your watchlist.
• Prioritise resilience by scanning for businesses in the 81 resilient stocks with low risk scores and see which names align with your appetite for steadier risk profiles.
• Get ahead of the crowd by checking the screener containing 25 high quality undiscovered gems and see which lesser known companies stand out on quality and fundamentals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.